Arena Pharma (ARNA) BELVIQ Trends Remain Underwhelming, BMO Capital Notes
Get Alerts ARNA Hot Sheet
Rating Summary:
10 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 7 | New: 9
Join SI Premium – FREE
BMO Capital analyst Jim Birchenough reiterated a Market Perform rating and $9 price target on Arena Pharma (NASDAQ: ARNA) following Q1 results, with BELVIQ trends remaining underwhelming.
Birchenough commented, "We are maintaining our Market Perform rating on the shares of ARNA following review of 1Q15 operating results. BELVIQ launch trends remain modest and efforts to stimulate growth so late in the launch cycle are unlikely to be successful, in our view. We believe that pipeline development remains critical but ARNA appears behind competition in developing oral alternatives to injectable drugs for autoimmune disease and PAH and features of differentiation appear unclear."
For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.
Shares of Arena Pharma closed at $4.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Double Downgrades AU Optronics (2409:TT) (AUO) to Underweight
- Hyatt Hotels (H) PT Lowered to $195 at Mizuho
- Evercore ISI Upgrades First Solar (FSLR) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!